(Oslo, Norway, 5 October 2016) Reference is made to the announcement on 14 September 2016 regarding the Rights Offering in Bionor Pharma ASA (the 'Company') and the announcement on 4 October 2016 regarding the final result of the Rights Offering.
STOCK EXCHANGE ANNOUNCEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES
After yesterday's allocation of shares in the Rights Offering, the primary insiders who were allocated shares in the Rights Offering holds the following interests in the Company:
Name | Position | Allocation of shares in the Rights issue | Warrants | Total number of shares after Rights Issue |
Per S. Thoresen through Bekkestua Venture AS | Board member | 1,183,690 | 0 | 1,183,690 |
Unni Hjelmaas through Hjelmaas AS | Acting CEO | 473,476 | 0 | 473,476 |
Jens Krøis | CFO | 195,499 | 105,600 | 301,099 |
Cecilie Grue through Grue Invest AS | Director of legal affairs | 195,499 | 105,600 | 301,099 |
Gunnar Flåten | Director of Finance | 800,000 | 0 | 1,617,500 |
Maja A. Sommerfelt | VP, Director of Research & External Innovation | 591,106 | 0 | 910,393 |
The subscription price for the shares in the Rights Offering was NOK 0.10 per share.
Further information
Unni Hjelmaas, Acting CEO, +47 915 19 651, uh@bionorpharma.com
Jens Krøis, CFO, +45 208 01 668, jk@bionorpharma.com
Link to the announcement in pdf
Bionor Pharma ASA published this content on 05 October 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 October 2016 11:09:02 UTC.
Original documenthttp://www.bionorpharma.com/en/Media/News/2016/Financial/Primary+insider+notification+–+Allocation+overview.b7C_wlDU3C.ips
Public permalinkhttp://www.publicnow.com/view/6DD71FB0E3D577459434DB17AA6BF8980AB50C57